Skip to content

Head to head

BPC-157 against KPV

Both are sold for gut inflammation and both are mostly preclinical. KPV is a tripeptide fragment of alpha-MSH with anti-inflammatory activity in models; BPC-157's only controlled human work was two rectal enema studies in Croatia.

Column A

BPC-157

Body Protection Compound 157

A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.

Column B

KPV

KPV (lysine-proline-valine, alpha-MSH fragment)

A small anti-inflammatory tripeptide derived from alpha-MSH studied for gut inflammation and skin, mostly in preclinical models.

Side by side, on the facts we can check

AttributeBPC-157KPV
CategoryHealing & RecoveryHealing & Recovery
FDA statusNot FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA actionNot FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6 to recommend for compounding (July 2026); awaiting FDA rulemaking
Half-lifeUnder 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days.Short
Molecular weight1,419.5 Da342.4 Da
MechanismIn animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days.Enters cells and suppresses pro-inflammatory NF-kB signaling, reducing inflammatory cytokine production.
Human studies cited50
Legal status, USNot approved; research use onlyNot approved; research use only
open the BPC-157 profileopen the KPV profile

Frequently asked questions

What is the difference between BPC-157 and KPV?

BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. KPV: A small anti-inflammatory tripeptide derived from alpha-MSH studied for gut inflammation and skin, mostly in preclinical models.

Which has stronger research evidence, BPC-157 or KPV?

This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 0 of 3 for KPV. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.

Are BPC-157 and KPV FDA-approved?

BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. KPV: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6 to recommend for compounding (July 2026); awaiting FDA rulemaking.

Related posts

Blog articles that cover BPC-157 or KPV, newest first.

Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.